Answered: The plaque assay plate below was made… | bartleby

Related questions

Question

The plaque assay plate below was made from a dilution of 10-7 and 0.1 ml of the dilution was
plated on the cell monolayer. What is the virus titer in PFU/ml? Note: 10e1 means 10 to the
first power, etc. Select all answers that apply.

Expert Solution

Step by step

Solved in 3 steps

SEE SOLUTION Check out a sample Q&A here

Blurred answer

Similar questions

a) did the positive and negative controls work correctly in this ELISA? Explain. B) in the sample wells( wells3-7) some are darker blue than others. Explain what happened here and how you'd interpret the results?
8. You infect E. coli cells with two strains of T4 virus. One strain is minute (m), rapid lysis (r) and turbid (t); the other is wild-type for all three markers. The lytic products of this dual infection are plated on a lawn of E. coli and the morphology of the plaques are classified. The resulting 10, 342 plaques were distributed among eight phenotypes, as follows: mrt 3467 +++ 3729 mr+ 853 m+t 162 m++ 520 +rt 474 +r+ 172 ++t 965 You decide to repeat the exact same experiment as outlined above and this time you count and classify 25, 000 plaques? How many plaques would you expect to be wild-type for all three markers? (Hint: You will need to calculate the expected DCO class for the cross above and apply that to your answer.)
Give typed full explanation
i found this past paper online and am using it for revision but i cannot find the mark scheme anywhere online. B2 Examples of intra-subject scatter plots between nystagmus intensity and BCVA with best-fit lines are shown in figure 3C for examples of individuals with grades 1 to 4 foveal hypoplasia. Slopes for the best-fit lines for each participant in which the r value were greater than 0.25 are shown in figure 3D. A positive slope predicts that reducing nystagmus improves BCVA. ii. What statistical parameters are generated by this approach and what do they mean?
Two of the vaccines being used to prevent SARS-CoV-2 infection (the virus causing COVID-19 disease) are made of RNA sequences derived from the viral genome, which are translated into antigenic proteins in the recipient's muscle cells. This is an example of a(n): Nucleic acid vaccine Inactivated whole-agent vaccine Attenuated whole-agent vaccine Toxoid vaccine Conjugated vaccine
You do a viral plaque assay using the six well plate shown below. The dilution scheme, what was infected on each well, and the results of the plaque assay are shown below. What is the viral titer of the original lysate? A. ~1.1 *10^6 PFU/mL B. ~1 *10^7 PFU/mL C. ~3 * 10^7 PFU/mL D. ~2 * 10^6 PFU/mL E. ~3.5 *10^6 PFU/mL F. ~1.1 * 10^5 PFU/mL G. ~3.5 *10^5 PFU/mL
Have a look at the results in this SDS-PAGE gel. A MW ladder is shown. In the "control" lane, a sample of recombinant protein "LBT3" was loaded. Lane A shows proteins that have been prepared from leukocytes from a normal, healthy individual. Lanes B, C, D, E and F show protein prepared from leukocytes from individuals with lymphoma. What is the best explanation for the result shown for patient D? 200 150 100 75 50 37 20 Weight, kDa MW ladder Control A
Please help me andchoose the right one and explain
how does the Pitzer vaccine uses cellular machinery to make the cell SARS-CoV-2 spike protein.
The N-95 mask is considered to be one of the safest masks. It’s pore size is 0.3 um. If that is so, how many covid 19 viral particles (side by side) could fit through one hole at a single time
You want to infect a plate of 2x10^6 HeLa cells with poliovirus at an MOI of 10. Your viral stock is at concentration of 8x10^7 particles/ml. What volume of your viral stock do you need to apply to your cells? Show your working
Following is the data and notice that it is a terrible idea to culture hMSCs longer than 10 days. You’re strongly Days # cells0 50001 75002 125003 125004 218005 287006 530007 1143008 1653009 19200010 19200011 11680012 8950013 8830014 78300 Part1 You are working for a start-up that is pursuing a clinical trial. The trial involves grafting hMSCs intopatients suffering from interveterbral disc disease using a degradable polymer scaffold. You are going to 3Dprint a porous cylindrical scaffold that is 2 cm in radius and 1 cm in height (matching the dimensions of adegenerated disc). Assume a porosity of 50%. You will fill available volume of the scaffold with hMSCs at adensity of 1 million cells per cm3. Based on the data above, what starting number of cells will you use andhow long will it take you to get enough cells for the trial? Part2The trial is a failure (patients did not report any reduction in back pain). Your team wants to try againusing 85% hMSCs and 15% nucleus pulposus cells .…

SEE MORE QUESTIONS